EBAMed key facts
as of Oct 2026- Developer of the next-generation radiation therapy technology designed to treat cardiac arrhythmias from outside the heart.
- EBAMed is valued at approximately $105.6M as of Oct 2026 (last reported valuation).
- It has raised $51.1M; the latest was Later Stage VC ($29.9M) in Jun 2025.
- Notable investors include MassChallenge, European Innovation Council, Venture Kick, CDP Venture Capital (Rome), European Union — 13 tracked in total.
- Status: Privately Held (backing).
EBAMed's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch EBAMed: the Monday email on marks, rounds and moves
EBAMed funding rounds
No funding rounds for EBAMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs EBAMed
13+EBAMed valuation
EBAMed's last reported valuation was $106 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
EBAMed investors
13 investors are on record for EBAMed, including MassChallenge, European Innovation Council, Venture Kick and CDP Venture Capital (Rome).
About EBAMed
Developer of the next-generation radiation therapy technology designed to treat cardiac arrhythmias from outside the heart. The company's device utilizes proton therapy, capable of selectively treating the tissues responsible for heart arrhythmias, enabling patients to undergo a non-invasive treatment in a single outpatient session.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2018
- Employees
- 3
- Website
- eba-med.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.